# How researchers defined hormone selectivity for ipamorelin

- Article ID: research-089
- Product: CJC-1295 (No DAC) / Ipamorelin (cjc-1295-ipamorelin-578)
- Canonical page: https://heritagebiolabs.com/research-library/articles/089-how-researchers-defined-hormone-selectivity-for-ipamorelin
- Product collection: https://heritagebiolabs.com/research-library/products/cjc-1295-no-dac-ipamorelin
- Product page: https://heritagebiolabs.com/product/cjc-1295-ipamorelin-578
- Reading focus: Mechanisms & biology (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 1998, 2024

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Short amino-acid chains held together by peptide bonds can act on receptors that influence more than one hormone. The label CJC-1295 (No DAC) / Ipamorelin refers to modified growth hormone–releasing factor (1–29) alongside a synthetic five-residue growth hormone secretagogue. In the original ipamorelin research, what did it mean to describe the compound as selective? [1, 2]

In a 1998 preclinical study, researchers used rat pituitary cells and animal experiments to compare ipamorelin with related peptides. In the cell experiments, ipamorelin stimulated growth hormone release through a growth hormone secretagogue–type receptor. In pigs, GHRP-2 and GHRP-6 increased two additional hormones, adrenocorticotropic hormone and cortisol. The researchers did not observe a significant difference between ipamorelin and the GHRH comparison for those two endpoints in the pig experiment. [2]

That is a comparison among named compounds, for measured hormones, in a specific species. It gives context for the term selective. It leaves open what would happen to other biological processes or with a different exposure, and does not establish that ipamorelin's selectivity in pigs would hold for a mixture in humans. A trial interested in selectivity would need to measure the hormones it claims to distinguish. [2, 3]

No recent primary study of the exact no-DAC and ipamorelin combination was identified for this question. The older work studied ipamorelin by itself and compared it with several reference compounds. Its design helps identify which observations justify a claim about a single peptide. The FDA's later review identifies gaps in the available clinical effectiveness and safety evidence for ipamorelin itself. A response observed in swine is a reason to test human selectivity directly under defined conditions. [1, 2, 3]

## Sources

1. U.S. Food and Drug Administration. December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting. FDA briefing document on CJC-1295-related bulk drug substances (publication 2024-12-04). <https://www.fda.gov/media/183819/download>
2. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology (publication 1998-11). <https://pubmed.ncbi.nlm.nih.gov/9849822/>
3. U.S. Food and Drug Administration. October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee. FDA briefing document on ipamorelin-related bulk drug substances (publication 2024-10-29). <https://www.fda.gov/media/182088/download>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 018 - CJC-1295 (No DAC) Ipamorelin.docx; article 89; content SHA-256 d7daf29e5e50073ba17e958795df9bf91e46d6fc2453a8d645d8156a306e368d.
